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Main conclusions and options for action 
Since December 2014, and as of 10 February 2015, 23 cases of botulism have been reported in Norway (eight 
cases) and Scotland (15 cases), affecting people who inject drugs (PWID). All the reported cases used heroin, 
and it is assumed that the source of the infections is contaminated heroin. The batch or batches of the heroin 
suspected of being contaminated with the spores of Clostridium botulinum have so far not been identified. It is 
therefore not possible to estimate the volume and distribution of contaminated heroin. However, the clustering of 
the cases in time and place suggest that the 23 cases could be linked to heroin from a common contaminated 
batch. 
People who inject drugs are known to be at risk of wound botulism. Guidance on drug treatment and prevention 
and control of infections among people who inject drugs has been issued by ECDC and the EMCDDA in 2011 [1]. 
No person-to-person transmission has ever been reported.  
The following measures are relevant for mitigating the risk of more cases of wound botulism in the EU/EEA 
Member States: 
• Increase awareness about wound botulism among physicians and other healthcare providers who provide 
care for PWID in order to reduce the lag time between onset of symptoms and diagnosis and treatment. 
• Increase awareness among heroin users, their social networks, and drug treatment and harm reduction 
services regarding the signs and symptoms suggestive of wound botulism infection. Emphasise the  
importance of seeking medical treatment immediately. 
• Encourage heroin users to reduce or eliminate heroin use as much as possible by promoting access to 
appropriately-dosed opiate substitution treatment.  
• Facilitate the exchange of information and guidelines on the investigation and control of wound botulism 
in PWID, e.g. case definitions, educational materials, investigation questionnaires, treatment protocols, 
and documents on communication strategies for vulnerable groups (see the materials developed by Public 
Health England [2,3]).  
• Continue forensic investigations at the national and EU/EEA levels to identify contaminated batches of  
heroin. 
• Ensure availability of antitoxin for the timely treatment of future cases. If large clusters of cases occur, 
mechanisms which facilitate the mobilisation of antitoxin in the EU/EEA need to be considered. 
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Public health issue 
Clusters of wound botulism among people who inject drugs (PWID) in Norway and in the UK. 
Source and date of request 
European Commission, 6 February 2015. 
Consulted experts 
ECDC internal response team: Niklas Danielsson, Alastair Donachie, Kaja Kaasik-Aaslav, Cornelius Bartels, Sergio 
Brusin. 
EMCDDA experts: Isabelle Giraudon, Lucas Wiessing, Joanna Sekula, Roland Simon 
Consulted external experts: Hans Blystad, Line Vold (Norwegian Institute of Public Health); Vivian Hope (Public 
Health England)  
Disease background information 
Botulism is a serious and potentially fatal paralytic illness caused by a toxin produced by the anaerobic bacterium 
Clostridium botulinum. There are three forms of disease depending on the site of toxin production: food-borne 
(ingestion of pre-formed toxin), intestinal, and wound. Wound botulism occurs when spores get into an open 
wound and reproduce in an anaerobic environment. Botulism is not spread from one person to another [4]. 
The botulinum toxin produces descending, flaccid paralysis without fever. Patients typically present with difficulty in 
speaking, seeing and swallowing. Symptoms are similar in all forms of botulism, but may take up to two weeks to 
appear in the wound form [4]. If untreated, paralysis may progress to the arms, legs, trunk and respiratory 
muscles. Treatment includes antibiotics and the administration of an antitoxin. The case–fatality rate is around 5 to 
10% for adequately treated patients.  
People who inject drugs are at risk of wound botulism because the bacterium can be deposited under the skin if 
the injected drug has been contaminated. Illicit drugs that have been associated with botulism are opiates (heroin) 
and stimulants (cocaine and amphetamine). The vast majority of reported cases have been associated with heroin 
use by intravenous, subcutaneous (‘skin-popping’) or intramuscular (‘muscle-popping’) injection routes [5].  
Since the first reported cases of wound botulism in 1994 in the United States, there has been an epidemic in 
people who inject drugs, especially in California. The epidemic has been associated with ‘skin popping’ ‘black tar 
heroin’ (BTH), a form of heroin that is predominantly used in the western United States. BTH is a low grade 
resinous form of heroin, often smuggled in from countries south of the United States [6]. Most cases in the USA 
have been sporadic. 
Clinically or microbiologically confirmed Clostridium botulinum infections among people who inject drugs have been 
described in the EU/EEA since 2000 [7]. Between 2000 and 2013, the United Kingdom reported 167 cases [8], 
Germany 21 cases [9], Ireland nine cases [10] , Italy nine cases [7], and the Netherlands one case [11]. 
The cases in the EU/EEA, in particular those in the United Kingdom, have been associated with heroin in the form 
of a brown powder that requires an acidic diluent [12]. Contaminated heroin has been implicated in four different 
outbreaks of wound botulism among people who inject drugs in Scotland [13], Germany [9], southern England 
[14] and Norway [15].  
It is assumed that contamination of heroin with botulism spores is common, given the non-sterile production 
methods, clandestine transportation, and the ubiquity of the C. botulinum spores in soil. Contamination is a risk at 
every stage, from production, storage, transport to the adding of bulking agents before sale (‘cutting’) [16]. 
Because Clostridium botulinum is an anaerobe bacterium, multiplication and symptomatic infection only occurs 
when the spores end up in a suitable anaerobic environment, such as damaged subcutaneous tissue and muscles. 
The bacterium does not grow in the blood. Most people who inject drugs use the intravenous route. The highest 
risk for botulism is among people who intentionally inject the drug intramuscularly or subcutaneously, but 
unintentional tissue deposits (‘missed hits’) can also result in infection. Heating the heroin powder to solubilise it 
for subcutaneous injection does not kill the spores. The use of an acidic diluent may increase tissue damage at the 
injection sites and thereby facilitate germination of botulinum spores [17]. Drug-related botulism has also been 
reported after sniffing cocaine [18]. 
 
 
 
 
RAPID RISK ASSESSMENT Wound botulism in people who inject heroin: Norway and the UK, 14 Feb 2015 
 
 
 
 
 
3 
Event background information 
On 26 December 2014, the Norwegian Institute of Public Health posted a message on the Early Warning and 
Response System (EWRS) about a case of botulism in a person who injects drugs (PWID). On 26 January 2015, 
Norway reported information about two additional possible cases. As of 10 February 2015, eight cases of wound 
botulism have been confirmed among people who inject heroin in Norway. All cases bought the heroin in the Oslo 
area [19]. One of the cases had not injected the heroin during the incubation period; he reported that he smoked 
the drug. 
Prior to the present cases, Norway reported 16 cases of wound botulism among PWID, including a cluster of three 
cases in 1997 [20] and a cluster of seven cases in 2013 [15].  
On 1 January 2015, NHS Greater Glasgow and Clyde's Public Health Protection Unit, Police Scotland and Health 
Protection Scotland (HPS) reported an investigation into two probable cases of botulism among PWID in the 
Greater Glasgow and Clyde area [21].  
From 21 December 2014 to 9 February 2015, 15 probable or confirmed cases of wound botulism were reported in 
Scotland. In the cases where information is available, the drugs were bought in, or sourced, via Glasgow.  
Of the six cases which were confirmed microbiologically, three are type B.  
Since 21 December 2014, 21 people have been admitted to hospital in Scotland with severe illness and suspected 
botulism. Seven of the suspected cases have been reported since 1 February 2015. Two of these 21 cases had 
other causes that could explain the symptoms, and four cases remain under investigation for botulism (these are 
currently not counted as probable cases). The hypothesis that all or some of these cases are linked to a single 
batch of contaminated heroin has yet to be substantiated. In the meantime, HPS continues to stress the urgency of 
communicating the risk of botulism associated with contaminated heroin [22]. 
The United Kingdom reported 167 cases of wound botulism among PWID between 2000 and 2013 [8] while no 
cases were reported before 2000. There are usually several sporadic cases of wound botulism among PWID 
reported each year [14]. The most recent cluster of cases in the UK was in 2009 [8].  
So far in 2015, one case of wound botulism among PWID has been reported in England. Investigations are 
ongoing, and this case is currently considered as a sporadic case with no links to the cases in Scotland or Norway. 
There have been no cases in Wales or Northern Ireland in recent years [23]. 
ECDC/EMCDDA joint threat assessment for 
the EU/EEA 
People who inject drugs frequently suffer from skin and soft tissue infections, and wound botulism is a well-
documented risk [12,24].  
Heroin, cutting agents or syringes that have been contaminated with Clostridium botulinum spores are the most 
likely sources of infection for this cluster of wound botulism among PWID in the EU/EEA [7]. Given the ubiquity of 
C. botulinum spores, contamination may happen during any of the stages of heroin production, cross-border 
transportation, distribution, ‘cutting’ before sale and preparation for injection. The highest risk for botulism is 
among people who intentionally inject the drug intramuscularly or subcutaneously, but unintentional tissue 
deposits (‘missed hits’) can also result in infection. Historically, both sporadic cases and clusters of wound botulism 
have occurred among PWID. When clusters occur, they tend to be limited to a certain geographic area. It has not 
been confirmed that the two clusters in Norway and Scotland are linked to a common supply of heroin. However, 
having large two clusters this close in time is unusual. 
People who inject drugs are continuously at risk of wound botulism because of the frequent penetrations of the 
skin, the ubiquity of the spores in the environment, and the possibility of using contaminated heroin. This 
background risk increases with the amount of contaminated heroin circulating in the EU and at what stage of the 
production and distribution chain the heroin was contaminated.  
It cannot be excluded that additional cases of wound botulism will occur among PWID. Investigation into the origin 
and supply routes of the implicated heroin could possibly identify other countries at risk.  
Botulism is a rare condition, and clinicians may not always consider wound botulism as the cause of disease. This 
may result in undiagnosed cases or late diagnosis, potentially leading to a more severe clinical outcome. It has 
been shown that a pragmatic public health prevention approach can have a strong effect on reducing the spread of 
blood-borne and other infections among people who inject drugs. Prevention is feasible and effective, if properly 
implemented [1]. 
As C. botulinum is not transmitted from person to person, the risk to the general population in relation to these 
23 cases detected in Norway and the UK is negligible.  
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Conclusions and options for action 
People who inject drugs are known to be at risk of wound botulism. Guidance on drug treatment and prevention 
and control of infections among people who inject drugs has been issued by ECDC and the EMCDDA in 2011 [1]. 
No person-to-person transmission has ever been reported.  
The clustering of cases in time and two geographical places suggest that the 23 cases of botulism in PWID, eight 
cases in Norway and 15 in Scotland, could be linked to contaminated heroin from a common batch. However, the 
batch or batches of the heroin suspected of being contaminated with the spores of Clostridium botulinum have so 
far not been identified. It is therefore not possible to estimate the volume and geographical distribution of 
contaminated heroin in Europe.  
The following measures are relevant for mitigating the risk of more cases of wound botulism in the EU/EEA 
Member States: 
• Increase awareness about wound botulism among physicians and other healthcare providers who provide 
care for PWID in order to reduce the lag time between onset of symptoms and diagnosis and treatment. 
• Increase awareness among heroin users, their social networks, and drug treatment and harm reduction 
services regarding the signs and symptoms suggestive of wound botulism infection. Emphasise the  
importance of seeking medical treatment immediately. 
• Encourage heroin users to reduce or eliminate heroin use as much as possible by promoting access to 
appropriately-dosed opiate substitution treatment.  
• Facilitate the exchange of information and guidelines on the investigation and control of wound botulism in 
PWID, e.g. case definitions, educational materials, investigation questionnaires, treatment protocols, and 
documents on communication strategies for vulnerable groups (see the materials developed by Public 
Health England )[2,3].  
• Continue forensic investigations at the national and EU/EEA levels to identify contaminated batches of  
heroin. 
• Ensure availability of antitoxin for the timely treatment of future cases. If large clusters of cases occur, 
mechanisms which facilitate the mobilisation of antitoxin in the EU/EEA need to be considered. 
ECDC and EMCDDA will continue to monitor all incoming information on the evolution and epidemiology of this 
outbreak. 
Contact 
For further information, please contact: info@ecdc.europa.eu or info@emcdda.europa.eu 
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